An interventional study of HYPOFRACTIONATED and NORMOFRACTIONATED in Breast Cancer Female, sponsored by UNICANCER. Active, not recruiting at 28 sites in France. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by UNICANCER · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Breast Neoplasms by UNICANCER — 15 open to participants now, 27 under way, 7 of them phase 3. Breast Neoplasms · UNICANCER.
Among the 64 studies in Breast Neoplasms by UNICANCER, this one is the 12th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2016, is one of 14 with no phase, reaches primary completion later than 2 of the 26 other live ones, and was the 33rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →15 of the 64 studies in Breast Neoplasms by UNICANCER are open now, in 9 countries. Recruiting first, the newest first:
UNICANCER · Sites in France
Ages 60+ · Women only
UNICANCER · Sites in Belgium, France, Greece and 4 more countries
Ages 35–45 · Women only
UNICANCER · Sites in France, Italy
Ages 40–74 · Women only · Healthy volunteers
UNICANCER · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Women only
UNICANCER · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 29 · Phase 3 15
First in 1994; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,265 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 170 across the 59 interventional studies, 467 across the 4 observational. Of the 36 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
UNICANCER is the lead sponsor of 219 studies on the registry; 52 are open to participants now.
3 of the studies in Breast Neoplasms by UNICANCER that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03246841UNICANCERInvestigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. | 2026-12-30 |
| NCT07120087UNICANCEREvaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk. | 2026-12-31 |
| NCT03275311UNICANCEREvolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 64 studies in Breast Neoplasms by UNICANCER, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The standard treatment of localized breast cancers consists of surgical removal of the tumor at the breast or removal of the entire breast and lymph nodes (sentinel lymph node and / or axillary dissection) with or without chemotherapy followed by radiotherapy on the breast or thoracic wall and the lymph node areas from 5 to 6.5 weeks.
Shorter radiotherapy treatments over 3 weeks for breast cancer without lymph node involvement have been equally effective and have no more side effects in several clinical trials involving several thousand patients. This called hypofractionated radiotherapy has become a standard for breast cancers in the absence of lymph node involvement in postmenopausal women.
The objective of the HypoG01 trial is to evaluate hypofractionated radiotherapy in women who require radiotherapy in the breast or chest wall and lymph node areas by comparing standard over 5 to 6.5 weeks and hypofractionated irradiation over 3 weeks analyzing the possible side effects and in particular the risk of lymphedema (swelling of the arm on the side treated) and the effectiveness of these treatments
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions per week. If the patient is candidate for a boost it will be provided as follows: * sequential boost with 40 Gy to CTV breast in 15 fractions and 16 Gy to CTV boost in 8 fractions * or simultaneous integrated boost (SIB) with 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fractions
Radiation: HYPOFRACTIONATED
50 Gy / 25 fractions, 2.0 Gy per fraction, 5 fractions per week. If the patient is candidate for a boost it will be provided as follows: * sequential boost with 50 Gy to CTV breast in 25 fractions and 16 Gy to CTV boost in 8 fractions * or simultaneous integrated boost (SIB) with 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fractions
Radiation: NORMOFRACTIONATED
40 Gy/ 15 fractions / 3 weeks
Also known as: Experimental Arm
50 Gy/ 25 fractions / 5 weeks
Also known as: Standard Arm
Arm Lymphedema
Occurrence radiation-induced late morbidity measured as lymphedema of the arm on the treated side at 3 years after adjuvant radiotherapy as follows: At least≥ 10% increased arm circumference measured 15 cm proximal and/or 10 cm distal of the olecranon of the treated side relative to the baseline value, compared to the contralateral side circumference also relative to its baseline value.
Time frame: At 3 years
Functional Assessment
Flexion/abduction of the upper arm will be assessed.
Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years
Aesthetics Assessment-FIBROSIS
Fibrosis as tissue induration, telangiectasia, oedema of the breast/chest wall and dyspigmentation will be evaluated according the LENT-SOMA scoring scale.
Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years
Aesthetics Assessment-BIS SCORE
The patient evaluates satisfaction on The Body Image Score (BIS) where has been added an extra question regarding clothing habits and furthermore based on the study by Lyngholm et al also 2 more questions regarding the satisfaction with the appearance of the treated breast after breast conservation with and without comparison to the opposite breast as done in the DBCG HYPOII trial. In addition, it will ask if the patient treated with breast conservation has had lipo-feeling injection in the breast during follow up.
Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years
Aesthetics Assessment-Global Cosmestic
The global cosmetic result after breast conservation will be based on Harris´ 4-point scale modified by Rune Gärtner et al
Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years
CTCAE Toxicity Assessment
Acute/ late toxicity will be assessed according to the flowchart and performed based on CTCAE V4
Time frame: Before treatment, every week of treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years
RTOG/EORTC Toxicity Assessment
Acute/ late toxicity will be assessed according to the flowchart and performed based on Toxicity Criteria of RTOG/EORTC
Time frame: Before treatment, every week of treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years
Cancer Related Events
Cancer related endpoints are secondary endpoints in this trial. It's a composite outcome taking into account all relapse events (locoregional, invasive disease, distant disease), breast-cancer specific survival, and causes of death as defined per DATECAN guidelines. All time to cancer related endpoints are defined as starting from the date of randomization until the event.
Time frame: 6 months after the last fraction received, every year during 5 years, 10 years
Cost-Utility
A cost-utility analysis comparing radiotherapy regimens will be performed based on QALYs
Time frame: Week 3 or week 7 of treatment according the treatment arm and boost realization
Quality of Life QLQ-C30
Patients' quality of life will be assessed using self-administered questionnaire EORTC QLQ-C30
Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years
Quality of Life EORTC BR23
Patients' quality of life will be assessed using self-administered questionnaire EORTC BR23
Time frame: Before treatment, week 3 or week 7 of treatment according the treatment arm and boost realization, 6 months after the last fraction received, every year during 5 years, 10 years
| Milestone | HYPOFRACTIONATED | NORMOFRACTIONATED |
|---|---|---|
| Started | 631 | 629 |
| Completed | 614 | 607 |
| Not completed | 17 | 22 |
Occurrence radiation-induced late morbidity measured as lymphedema of the arm on the treated side at 3 years after adjuvant radiotherapy as follows: At least≥ 10% increased arm circumference measured 15 cm proximal and/or 10 cm distal of the olecranon of the treated side relative to the baseline value, compared to the contralateral side circumference also relative to its baseline value.
| Participants | HYPOFRACTIONATED | NORMOFRACTIONATED |
|---|---|---|
| Arm Lymphedema | 143 | 132 |
Flexion/abduction of the upper arm will be assessed.
Results for this outcome have not been posted.
Fibrosis as tissue induration, telangiectasia, oedema of the breast/chest wall and dyspigmentation will be evaluated according the LENT-SOMA scoring scale.
Results for this outcome have not been posted.
The patient evaluates satisfaction on The Body Image Score (BIS) where has been added an extra question regarding clothing habits and furthermore based on the study by Lyngholm et al also 2 more questions regarding the satisfaction with the appearance of the treated breast after breast conservation with and without comparison to the opposite breast as done in the DBCG HYPOII trial. In addition, it will ask if the patient treated with breast conservation has had lipo-feeling injection in the breast during follow up.
Results for this outcome have not been posted.
The global cosmetic result after breast conservation will be based on Harris´ 4-point scale modified by Rune Gärtner et al
Results for this outcome have not been posted.
Acute/ late toxicity will be assessed according to the flowchart and performed based on CTCAE V4
Results for this outcome have not been posted.
Acute/ late toxicity will be assessed according to the flowchart and performed based on Toxicity Criteria of RTOG/EORTC
Results for this outcome have not been posted.
Cancer related endpoints are secondary endpoints in this trial. It's a composite outcome taking into account all relapse events (locoregional, invasive disease, distant disease), breast-cancer specific survival, and causes of death as defined per DATECAN guidelines. All time to cancer related endpoints are defined as starting from the date of randomization until the event.
Results for this outcome have not been posted.
A cost-utility analysis comparing radiotherapy regimens will be performed based on QALYs
Results for this outcome have not been posted.
Patients' quality of life will be assessed using self-administered questionnaire EORTC QLQ-C30
Results for this outcome have not been posted.
Patients' quality of life will be assessed using self-administered questionnaire EORTC BR23
Results for this outcome have not been posted.
Collected over The median follow-up time was 4.8 years after randomization.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HYPOFRACTIONATED | 36/630 (5.7%) | 21/630 (3.3%) | 617/630 (97.9%) |
| NORMOFRACTIONATED | 51/629 (8.1%) | 16/629 (2.5%) | 613/629 (97.5%) |
| Event | HYPOFRACTIONATED | NORMOFRACTIONATED |
|---|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 1/630 | 2/629 |
| CARDIAC FAILURECardiac disorders | 1/630 | 1/629 |
| BREAST HAEMATOMAReproductive system and breast disorders | 0/630 | 1/629 |
| DEVICE RELATED INFECTIONInfections and infestations | 0/630 | 1/629 |
| DIABETES MELLITUS INADEQUATE CONTROLMetabolism and nutrition disorders | 0/630 | 1/629 |
| ERYSIPELASInfections and infestations | 0/630 | 1/629 |
| FAT NECROSISGeneral disorders | 0/630 | 1/629 |
| FATIGUEGeneral disorders | 0/630 | 1/629 |
| IMMUNE THROMBOCYTOPENIC PURPURABlood and lymphatic system disorders | 0/630 | 1/629 |
| LYMPHOCELEVascular disorders | 0/630 | 1/629 |
| Event | HYPOFRACTIONATED | NORMOFRACTIONATED |
|---|---|---|
| RADIATION SKIN INJURYInjury, poisoning and procedural complications | 520/630 | 561/629 |
| PAINGeneral disorders | 412/630 | 434/629 |
| FATIGUEGeneral disorders | 401/630 | 401/629 |
| FIBROSISGeneral disorders | 306/630 | 277/629 |
| PRURITUSSkin and subcutaneous tissue disorders | 139/630 | 191/629 |
| LYMPHOEDEMAVascular disorders | 191/630 | 183/629 |
| RESPIRATORY DISORDERSRespiratory, thoracic and mediastinal disorders | 147/630 | 175/629 |
| DYSPHAGIAGastrointestinal disorders | 132/630 | 154/629 |
| DYSPIGMENTATIONSkin and subcutaneous tissue disorders | 107/630 | 123/629 |
| BREAST/NIPPLE OEDEMAReproductive system and breast disorders | 71/630 | 72/629 |
| Age, Continuous(years) | HYPOFRACTIONATED | NORMOFRACTIONATED | Total |
|---|---|---|---|
| Mean | 58.5 ± 13.1 | 58.2 ± 12.5 | 58.3 ± 12.8 |
| Age, Continuous(years) | HYPOFRACTIONATED | NORMOFRACTIONATED | Total |
|---|---|---|---|
| Mean | 58.5 ± 13.1 | 58.2 ± 12.5 | 58.3 ± 12.8 |
| Sex: Female, Male(Participants) | HYPOFRACTIONATED | NORMOFRACTIONATED | Total |
|---|---|---|---|
| Female | 614 | 607 | 1221 |
| Male | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | HYPOFRACTIONATED | NORMOFRACTIONATED | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
The record gives a start of Sep 2016, a primary completion of Dec 2022 and a completion of Sep 2030. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2026, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.